Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cordis Unveils CoCr Coronary Stent
The Presillion Plus changes include a new hypotube for improved pushability in crossing calcified lesions and a redesigned semi-compliant balloon for precise stent deployment and decreased deflation time.
The Presillion Plus changes include a new hypotube for improved pushability in crossing calcified lesions and a redesigned semi-compliant balloon for precise stent deployment and decreased deflation time.
According to the prescribing information, the patients, who are designated as poor metabolizers, represent nearly 2% of whites, 4% of blacks, and 14% of Chinese. The percentage of
Income from operations was RMB28.6m, a decrease of 66.6% from the fourth quarter of 2008. Net income attributable to shareholders was RMB34.8m, a decrease of 50.5%. For the
Under the terms of the agreement, Sigma-Aldrich has the rights to manufacture and sell the RAFT agents worldwide for all research and development applications. The RAFT agents are
Under the plan, Oximeplus, a Teijin group company and home healthcare equipment provider based in Andalusia, Spain, has been renamed Esteve Teijin Espana (ETE) to better leverage the
The new racking system offers a better use of space, efficient processing and a hygienic containment for parts belonging to machinery used in the production of sensitive products
Inecalcitol is an orally active agonist targeting the vitamin D receptor. The therapeutic rationale behind its development is to add its cytostatic potential to the established efficacy of
The ELISA format of the AppyScore Test is currently in clinical trials for clearance by the FDA and is designed to aid in the evaluation of patients suspected
Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60%
The lurasidone NDA includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients. The efficacy and safety of lurasidone were evaluated in five six-week,